{"slug":"vip-tirzepatide","verification":{"valid":true,"entries":5,"head":"ab99dd7f9e56aef8928250f37f2fa65436b23973637fc96cb23b36edbc1684e1"},"count":5,"sources":[{"id":"s2","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"We investigated safety and efficacy of VIP inhalation in eight PPH patients...","summary":"Small human study on VIP inhalation in pulmonary hypertension.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"d4b38164dd83af323e43c68dede9f90e29c3b8e1e60c80fc4bce9fae07245f4a"},{"id":"s4","type":"pubmed","url":"https://www.hippokratia.gr/vasoactive-intestinal-peptide-inhaled-agonists-potential-role-in-respiratory-therapeutics/","title":"Vasoactive Intestinal Peptide Inhaled Agonists","quote":"Twenty four patients were studied in a double blind placebo controlled trial...","summary":"Describes asthma trial with VIP analogue.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"d4b38164dd83af323e43c68dede9f90e29c3b8e1e60c80fc4bce9fae07245f4a","hash":"81fa041362c632fc407baa1e9cf544ec5f16efc02ccc07a47ecc58b1d5f0fa7e"},{"id":"s6","type":"other","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"VIP prevents experimental arthritis","quote":"VIP has a therapeutic effect on an animal model of rheumatoid arthritis.","summary":"Summary of rat arthritis study with VIP.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"verified","prev":"81fa041362c632fc407baa1e9cf544ec5f16efc02ccc07a47ecc58b1d5f0fa7e","hash":"c702d30f2dbaefe6604b70e4d48d1a53b3e8f8047c8a31cfe329a4f06647e688"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/","title":"The SURMOUNT-4 Randomized Clinical Trial","quote":"Participants ... experienced a mean weight reduction of 20.9%. ... overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide","summary":"Key tirzepatide weight loss maintenance trial results.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"c702d30f2dbaefe6604b70e4d48d1a53b3e8f8047c8a31cfe329a4f06647e688","hash":"9f303514771d8c574588de1cc1416494e6571eb9514be7d7f813777edf12b7ac"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883350/","title":"Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions","quote":"VIP affects both innate and adaptive immune responses and acts as a major anti-inflammatory factor in animal models","summary":"Review of VIP immune effects in preclinical models.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"verified","prev":"9f303514771d8c574588de1cc1416494e6571eb9514be7d7f813777edf12b7ac","hash":"ab99dd7f9e56aef8928250f37f2fa65436b23973637fc96cb23b36edbc1684e1"}]}